Results 101 to 110 of about 1,096 (177)
Novel Role for Matrix Metalloproteinase 9 in Modulation of Cholesterol Metabolism
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundThe development of atherosclerosis is strongly linked to disorders of cholesterol metabolism. Matrix metalloproteinases (MMPs) are dysregulated in patients and animal models with atherosclerosis.
Samuel Hernandez‐Anzaldo +10 more
doaj +1 more source
, 2017 Snakebite envenoming is a neglected tropical disease that kills >100,000 people and maims >400,000 people every year. Impoverished populations living in the rural tropics are particularly vulnerable; snakebite envenoming perpetuates the cycle of poverty.
Calvete, Juan J +5 more
core +3 more sources
Emerging drugs for sickle cell anemia. [PDF]
, 2015 INTRODUCTION: The search for effective therapeutic interventions for sickle cell disease (SCD) has been an ongoing endeavor for over 50 years. During this period, only hydroxyurea (HU), which received US FDA approval in February 1998, was identified as ...
Ballas, Samir K., Singh, Priya C
core +1 more source
Neutralizing properties of Varespladib toward group I and II myotoxic phospholipases A2
, 2020 A need exists to develop specific and clinically useful inhibitors of toxic enzymes present in snake venoms, responsible for severe tissue damage and life-threatening effects occurring in thousands of people suffering envenomations globally. LY315920 (Varespladib, S-5920, A-001), a low molecular weight drug developed to inhibit several human secreted ...
Bryan Quirós, Wendy +4 more
openaire +2 more sources
A concise review on copper catalyzed synthesis of α-ketoamides
Applied Catalysis O: OpenThe α-ketoamides are essential building blocks for the synthesis of β-lactams and oxazolidinones. As it contains multiple reactive centers, it could be a suitable starting material for following reactions such as Michael addition reaction, Pictet ...
Amit Gautam +4 more
doaj +1 more source
Human Genomics and Drug Development [PDF]
, 2022 Insights into the genetic basis of human disease are helping to address some of the key challenges in new drug development including the very high rates of failure.
Finan, C, Hingorani, AD, Schmidt, AF
core
Structural Elements Of Lipidic Inhibitors Of Phospholipase A2 [PDF]
, 2018 Phospholipases A2 (PLA2) are a family of enzymes that release fatty acids from phospholipids and play varied and important roles in the biology of all organisms. Secreted phospholipases A2 (sPLA2) are the largest subfamily of PLA2.
Foley, James +1 more
core
Journal of Translational MedicineBackground In mouse models of atherosclerosis, knockout of the PLA2G2A gene has been shown to reduce the volume of atherosclerotic plaques. Clinical trials have demonstrated the potential of using the sPLA2 inhibitor Varespladib in combination with ...
Xin Wang +9 more
doaj +1 more source
The genetic architecture of Secretory PLA2 (sPLA2)genes and their impact on sPLA2 activity/mass and association with CHD risk. [PDF]
, 2012 Secretory phospholipase A2 group (sPLA2) enzymes hydrolyze the sn-2 ester bond of phospholipids, producing lysophospholipids and free fatty acids. SPLA2s have been identified as biomarkers of atherosclerosis in observational and animal studies.
Exeter, HJ
core
22 New Anti-Inflammatory Therapy for Neonatal Acute Lung Injury: Varespladib (A-001) Inhibits Ex-Vivo Secretory Phospholipase [PDF]
, 2010 Danièle De Luca +4 more
openalex +1 more source